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Background: Endothelial dysfunction is a crucial early phenomenon in vascular diseases linked to diabetes mellitus
and associated to enhanced oxidative stress. There is increasing evidence about the role for pro-inflammatory
cytokines, like interleukin-1β (IL-1β), in developing diabetic vasculopathy. We aimed to determine the possible
involvement of this cytokine in the development of diabetic endothelial dysfunction, analysing whether anakinra,
an antagonist of IL-1 receptors, could reduce this endothelial alteration by interfering with pro-oxidant and
pro-inflammatory pathways into the vascular wall.
Results: In control and two weeks evolution streptozotocin-induced diabetic rats, either untreated or receiving
anakinra, vascular reactivity and NADPH oxidase activity were measured, respectively, in isolated rings and homogenates
from mesenteric microvessels, while nuclear factor (NF)-κB activation was determined in aortas. Plasma levels of IL-1β
and tumor necrosis factor (TNF)-α were measured by ELISA. In isolated mesenteric microvessels from control
rats, two hours incubation with IL-1β (1 to 10 ng/mL) produced a concentration-dependent impairment of
endothelium-dependent relaxations, which were mediated by enhanced NADPH oxidase activity via IL-1 receptors.
In diabetic rats treated with anakinra (100 or 160 mg/Kg/day for 3 or 7 days before sacrifice) a partial improvement
of diabetic endothelial dysfunction occurred, together with a reduction of vascular NADPH oxidase and NF-κB
activation. Endothelial dysfunction in diabetic animals was also associated to higher activities of the pro-inflammatory
enzymes cyclooxygenase (COX) and the inducible isoform of nitric oxide synthase (iNOS), which were markedly
reduced after anakinra treatment. Circulating IL-1β and TNF-α levels did not change in diabetic rats, but they were
lowered by anakinra treatment.
Conclusions: In this short-term model of type 1 diabetes, endothelial dysfunction is associated to an IL-1
receptor-mediated activation of vascular NADPH oxidase and NF-κB, as well as to vascular inflammation. Moreover,
endothelial dysfunction, vascular oxidative stress and inflammation were reduced after anakinra treatment. Whether this
mechanism can be extrapolated to a chronic situation or whether it may apply to diabetic patients remain to be
established. However, it may provide new insights to further investigate the therapeutic use of IL-1 receptor antagonists
to obtain vascular benefits in patients with diabetes mellitus and/or atherosclerosis.
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Vascular disease is a common feature in patients with
diabetes mellitus, impaired glucose tolerance, and obe-
sity. Diabetic vasculopathy is associated with endothelial
dysfunction and impaired vascular reactivity through a
mechanism that involves the over-production of reactive
oxygen species, as observed in both humans and experi-
mental animal models [1-9].
In addition to oxidative stress, other mechanisms are
participating in diabetic vasculopathy, including insulin
resistance and increased systemic and vascular inflam-
mation [10]. In this context, increasing evidence sup-
ports the participation of pro-inflammatory cytokines in
the development of vascular diseases, such as athero-
sclerosis and diabetic vasculopathy [11-14]. In particular,
interleukin-1β (IL-1β) has been involved in the patho-
genesis of type 1 and type 2 diabetes [15,16], as well as
in the development of the diabetic retinopathy asso-
ciated to type 1 diabetes [17,18]. Accordingly, the anta-
gonism of IL-1 receptors has been recently proposed as
a pharmacological target for the treatment of type 2 dia-
betes [19-21].
Despite all these observations, few data are available
about the possible involvement of pro-inflammatory cyto-
kines, and particularly IL-1β, in diabetic-induced endothe-
lial dysfunction, although the ability of this cytokine to
generate an impairment of endothelium-dependent rela-
xations has been previously reported in mesenteric arte-
ries from non-diabetic rats [22-24]. In the present work,
we tested the hypothesis that vascular inflammation me-
diated by cytokines, such as IL-1β, may play an important
role in the development of diabetic endothelial dysfunc-
tion. Using a short-term model of streptozotocin-induced
diabetic rat, we found that anakinra, a recombinant hu-
man antagonist of IL-1 receptors [25] improves the endo-
thelial dysfunction observed in the isolated mesenteric
microvasculature. Additionally, we found that such effects
of anakinra were likely mediated by interfering with the
pro-oxidant and pro-inflammatory mechanisms triggered
by diabetes into the vascular wall.
Methods
Ethical approval
All animal studies were performed according to national
and European guidelines (2010/63/EU), approved by the
ethics committee of Universidad Autónoma de Madrid
(CEI 27–670), and developed in registered animal faci-
lities (ES-28079-000097).
Experimental animals
In 16-week male old Sprague–Dawley (SD) rats (300 to
350 g), insulin-dependent diabetes was induced by a
single administration of streptozotocin (60 mg kg−1; i.p.).
After 72 hours, tail blood samples were obtained andglucose concentration was measured using a glucometer
Optium Xceed (MediSense, Abbott Laboratories, Chicago,
IL, USA). Diabetes induction was considered successful
when glycaemia was higher than 20 mmol/L. Control age-
and mass-matched rats were injected with saline solution
and kept in similar conditions as diabetic animals. All the
animals had ad libitum access to food (standard rat chow
diet) and tap water. The experimental animals were sepa-
rated into eight groups schematized in Figure 1.
Drug effects on vascular tone of mesenteric microvessels
The animals were briefly exposed to a chamber filled
with carbon dioxide until they fell unconscious and then
immediately killed by cervical dislocation. The mesen-
tery was removed, and placed in a Petri dish containing
Krebs-Henseleit solution (KHS) at 4°C. The third branch
mesenteric arteries were dissected in control and dia-
betic rats (mean internal diameter ranged between 200
and 400 μm; non-significant differences were observed
among the different groups of rats). The arteries were
dissected and cleaned free of fat and connective tissue
under a light microscope and mounted as ring pre-
parations on a small vessel myograph [6] to measure iso-
metric tension. Arteries were bathed in KHS at 37°C
continuously bubbled with a 95% O2-5% CO2 mixture,
which yields a pH of 7.4 and their passive tension and
internal circumference were determined. The arteries
were subjected to optimal tension (90% of the tension
equivalent to a intramural pressure of 100 mm Hg. After
30 min of equilibration, the vessels were exposed to
125 mmol/L KCL (KKHS, equimolar substitution of KCl
for NaCl in KHS) for 2 min in order to check their func-
tional integrity. Segments failing to achieve a maximum
active tension equivalent to a pressure of 100 mmHg
were rejected [6].
The bath was then washed three times with KHS and
a further 150 min washout period was allowed before
the arteries were contracted with the concentration of
NA (1 μmol/L) required to produce approximately 80%
of the maximum response to KKHS. Relaxations to ACh
were subsequently assessed by adding cumulative con-
centrations of the drug at 2 min intervals (final bath
concentrations 0.1 nmol/L to 10 μmol/L). Some micro-
vessels were pre-incubated with increasing concentra-
tions of IL-1β (1, 2.5, 5, or 10 ng/mL) 120 min before
and during the administration of NA and ACh. Other
vascular segments were treated with the IL-1 receptors
antagonist anakinra (10, 50, or 100 μg/mL), the inhibitor
of NADPH oxidase activity apocynin (10 μmol/L), the
anion superoxide scavenger tempol (100 μmol/L), the cy-
clooxygenase (COX) inhibitor indomethacin (10 μmol/L),
or the blocker of the inducible isoform of nitric oxide syn-
thase (iNOS) 1400 W (10 μmol/L), for 30 min in advance
and during the administration of IL-1β, NA, and ACh,
Figure 1 Diagram for animal treatments. Diagram of the different designed rat groups, both in control conditions or after diabetes mellitus
induced by i.p. administration of streptozotocin (STZ). The animals received further i.p. administration of saline and/or anakinra (AK) before
sacrifice in day 15.
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ACh, concentration-dependent curves to the endothelium-
independent vasodilator sodium nitroprusside (SNP; 1
nmol/L to 10 μmol/L) were performed.
NADPH oxidase activity assay
The activity of NADPH oxidase was measured in rat
microvascular preparations by lucigenin-derived chemi-
luminiscence, as previously described [26]. In these ex-
periments, the mesenteric arteries were dissected, as
previously indicated and homogeneously distributed into
tubes containing 1 mL KHS at 37°C continuously bubbled
with a 95% O2-5% CO2 mixture. When appropriate, the
microvessels were treated for 30 min with 2.5 ng/mL
IL-1β, in the absence or in the presence of anakinra (100
μg/mL) or apocynin (10 μmol/L). Afterwards, the micro-
vascular preparations were homogenized in lysis buffer (pH
7.0) containing 50 mmol/L KH2PO4, 1 mmol/L EGTA and
150 mmol/L sucrose at 4°C. For every sample, the protein
content was determined by the bicinchoninic acid method.
Microvascular extracts were then incubated in phosphate-
buffered saline containing 5 mmol/L lucigenin with or
without 100 mmol/L NADPH. Luminescence was then
measured every 10 seconds for 5 minutes in a microplate
luminometer (Orion II Microplate Luminometer, Berthold
Technologies, Bad Wildbad Germany). For every sample,
NADPH oxidase activity was calculated as the difference
between the activities obtained in the presence and in theabsence of NADPH. The enzymatic activity was expressed
as relative light units (RLU)/mg of protein/min.
In situ detection of activated NF-κB
Southwestern histochemistry is a non-radiactive tech-
nique developed for in situ detection of activated tran-
scription factors, as described in detail previously [27].
This method requires the use of a double-strand DNA
containing the consensus sequence of NF-κB. In brief,
NF-κB consensus oligonucleotides were digoxigenin la-
beled with a 3’-terminal transferase. Paraffin-embedded
tissue sections were fixed in 0.5% paraformaldehyde and
subsequently digested with 0.5% pepsin and 0.1 mg/mL
DNaseI. Samples were then incubated at 37°C with 12
pmol/L of digoxigenin-labeled NF-κB probe in buffer
containing 0.25% BSA and 2 μg/mL poly(dI-dC), followed
by alkaline phosphatase-conjugated anti-digoxigenin IgG
and colorimetric detection with nitro blue tetrazolium/
5-bromo-4-chloro-3-indolyl phosphate toluidine salt (NBT/
BCIP). The nuclear staining in blue gives evidence for acti-
vated transcription factor. To verify the specificity of the
Southwestern histochemistry, three different controls were
systematically performed [28]: (1) Competition assay: in-
cubation with a 200-excess of unlabeled probe reduced
the intensity of the nuclear staining; (2) Mutant labeled
probe: serial slides were incubated under the same condi-
tions with consensus NF-κB probe or a mutant probe
(with a modification in the NF-κB binding site). A very
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pared with consensus probe, demonstrating the specificity
of the DNA binding; and (3) Negative control: no staining
was observed in the absence of labeled probe.
Cytokine determinations
At the time of the experiment, blood plasma samples were
collected and stored at −80°C until assay were performed.
Plasmatic IL-1β and tumour necrosis factor (TNF)-α levels
were determined by ELISA (ELx800 Bio-Tek Instruments,
Winoski, VT, USA) using an ELISA commercial kit (Gen
Probe/Diaclone, San Diego, CA, USA).
Materials
The composition of KHS (mmol/L) was NaCl 115, CaCl2
2.5, KCl 4.6, KH2PO4 1.2, MgSO4
. 7H2O 1.2, NaHCO3 25,
glucose 5.5 and Na2EDTA 0.03. Recombinant IL1β was
obtained from PeproTech (PeproTech GmbH, Hamburg,
Germany) while anakinra (Kineret©) was obtained from
Biovitrum (Swedish Orphan Biovitrum AB, Stockholm,
Sweden). Streptozotocin, NA, KCl, ACh, SNP, indome-
thacin, 1400 W, apocynin, tempol, lucigenin, and, unless
otherwise stated, all other reagents were purchased from
Sigma Chemical Co. (St. Louis, MO, USA). Noradren-
aline was prepared in saline (0.9% NaCl)-ascorbic acid
(0.01% w/v). Streptozotocin was dissolved in citric acid-
trisodium citrate (0.1 mmol/L) buffer with a pH of 4.5.
Lucigenin and NADPH were dissolved in saline solution
with 0.1 mmol/L EDTA, and 10 mmol/L Tris/HCl,
respectively. All other drug solutions were made in
distilled water.
Statistical analysis
Results are expressed as mean ± standard error (SEM).
pEC50 values for ACh were defined as the negative log
of the effective concentrations required to produce half
the maximum effect. In the figures, n means the number
of vascular segments used. Statistical analysis was per-
formed using two-factor ANOVA for curves or Student’s
t-test for data points, with the level of significance
chosen at p < 0.05.
Results
Effects of IL-1β on endothelium-dependent relaxations
When isolated mesenteric microvessels from SD rats were
incubated for 2 hours with IL-1β (1 to 10 ng/mL), there
were no changes in the contractile responses to 1 μmol/L
NA (10.19 ± 0.90, 12.13 ± 0.81, 9.09 ± 1.24, 11.85 ± 1.21,
and 10.51 ± 3.56 mNewtons, for control and segments
treated with 1, 2.5, 5, and 10 ng/mL IL-1β, respectively),
while a concentration-dependent impairment of the
endothelium-derived relaxations induced by ACh was
observed (Figure 2A). On the other hand, IL-1β (2.5, 5,
and 10 ng/mL IL-1β, respectively) did not affect theendothelium-independent relaxations evoked by SNP
(Figure 2B). A submaximal concentration of 2.5 ng/mL
IL-1β was used in the next experiments.
The impairment of endothelium-dependent relaxations
evoked by IL-1β was antagonized by the competitive in-
hibitor of IL-1 receptors anakinra (10, 50, and 100 μg/mL)
in a concentration-dependent manner (Figure 3A). Ana-
kinra neither affected the ACh-evoked vasodilatations in
the absence of IL-1β (data not shown) nor the NA-
induced contractility (8.94 ± 0.87, 9.10 ± 0.99, 12.07 ± 1.33,
10.98 ± 0.75, and 9.86 ± 1.56 mNewtons, in control and
10, 50, or 100 μg/mL AK, respectively). The endothelium
impairment induced by 2.5 ng/mL IL-1β was blunted by
pre-incubating the vascular segments with the NADPH
oxidase inhibitor apocynin (10 μmol/L) (Figure 3B) and
partially prevented by the anion superoxide scavenger
tempol (100 μmol/L) (Figure 3C). On the other hand,
no role for pro-inflammatory enzymes, such as COX or
iNOS, was observed for the endothelial dysfunction
evoked by IL-1β, as it was not modified by the inhibition of
COX with indomethacin (10 μmol/L) (Figure 3D) or by the
blockade of iNOS with 1400 W (10 μmol/L) (Figure 3E).
None of these treatments did modify the contractile
responses evoked by 1 μmol/L NA (data not shown).
Effects of IL-1β on microvascular NADPH oxidase activity
After treating isolated mesenteric arteries from control SD
rats with IL-1β (1, 2.5, and 10 ng/mL), a concentration-
dependent enhancement of the NADPH oxidase acti-
vity was observed in the microvascular preparations
(Figure 4A). The enhancement of the enzymatic activation
evoked by a submaximal concentration of 2.5 ng/mL
IL-1β was abolished by both anakinra (100 μg/mL) and
apocynin (10 μmol/L; Figure 4B).
Effects of in vivo treatment with anakinra on diabetic
endothelial dysfunction
In accordance to our previous report [7], two weeks of
diabetes evolution after streptozotocin administration
were required to develop significant endothelial dysfunc-
tion in the mesenteric microvessels isolated from dia-
betic rats. However, no modifications were observed in
the contractile responses to 1 μmol/L NA (10.39 ± 0.75
and 10.30 ± 0.96 mNewtons for control and diabetic rats,
respectively), nor in the endothelium-independent rela-
xations to SNP (data not shown). When the diabetic rats
received 100 mg/Kg/day anakinra during three days
prior to sacrifice, a significant improvement of the
diabetic endothelial dysfunction was observed, despite a
residual endothelial impairment (Figure 5A). Such re-
covery of endothelial function was not further amelio-
rated by expanding the treatment with anakinra for
7 days (Figure 5B). The administration of a higher dose
of anakinra (160 mg/Kg/day for 3 days) produced a
Figure 2 IL-1β impairs vascular reactivity. (A) Effect of IL-1β (1, 2.5, 5, and 10 ng/mL) on the endothelium-dependent relaxations induced by
acetylcholine (ACh, 0.1 nmol/L to 10 μmol/L) in isolated mesenteric arteries from control Sprague–Dawley (SD) rats. Data are expressed (means ± SE) as
the percentage of the previous contraction induced with 1 μmol/L noradrenaline (NA). The number of segments used for every curve, which were
obtained from 5 to 12 animals, as well as the statistical significance are in parenthesis. (B) Effect of IL1β (2.5, 5, and 10 ng/mL) on the endothelium-
independent relaxations induced by sodium nitroprusside (SNP, 1 nmol/L to 10 μmol/L) in isolated mesenteric arteries from control SD rats. Data are
expressed as the percentage of the pre-contraction induced with 1 μmol/L NA. The number of segments used for every curve, which were obtained
from 4 animals, as well as the statistical significance are in parenthesis.
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ACh-induced dependent relaxations when compared
with 100 mg/Kg/day anakinra for 7 days (p < 0.05), al-
though a residual endothelial dysfunction still persisted
(Figure 5C). None of the doses of anakinra used did
modify endothelium-dependent relaxations in vessels
from non-diabetic animals (Figures 5A, 5B, and 5C) or
the contractile responses evoked by 1 μmol/L NA in
control and diabetic animals (data not shown).
NADPH oxidase activity and NF-κB activation in the
vascular wall from diabetic rats
In mesenteric microvascular preparations obtained from
diabetic rats after two weeks of evolution, there was a
significant increase in NADPH oxidase activity, which
was significantly reduced when the isolated vessels were
treated 30 min before determination with 10 μmol/Lapocynin (Figure 6A). When the mesenteric microvessels
were obtained from diabetic animals receiving anakinra
(160 mg/Kg/day for 3 days), a marked reduction in
NADPH-oxidase enzymatic activity was also observed
(Figure 6A).
NF-κB activation was localized by Southwestern his-
tochemistry in aortas from control and diabetic rats
untreated or receiving 160 mg/Kg day for 3 days. The ar-
terial sections were hybridized with an oligonucleotide
containing the consensus sequence of the NF-κB recog-
nition site. As shown in Figure 6B, the sections from
control animals, treated or not with anakinra, did not
show any staining for NF-κB. On the contrary, sections
from diabetic rats showed a significant increase in nuclei
activation, which was reduced by treatment with ana-
kinra (Figure 6B). The quantification of activated nuclei
is depicted in Figure 6C.
Figure 3 Mechanisms involved in the endothelium impairment by IL-1β. Effects of (A) anakinra (AK, 10, 50, and 100 μg/mL), (B) apocynin
(Apo; 10 μmol/L), (C) tempol (100 μmol/L), (D) indomethacin (Indo; 10 μmol/L), or (E) 1400 W (10 μmol/L) on the impairment produced by
2.5 ng/mL IL-1β on the endothelium-dependent relaxations induced by ACh (0.1 nmol/L to 10 μmol/L) in isolated mesenteric arteries from
control SD rats. Data are expressed (means ± SE) as the percentage of the previous contraction induced with 1 μmol/L NA. The number of
segments used for every curve, which were obtained from 3 to 14 animals, as well as the statistical significance are in parenthesis.
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vascular wall on diabetic endothelial dysfunction
The endothelial dysfunction induced in mesenteric micro-
vessels by two weeks evolution diabetes involved the acti-
vation of vascular pro-oxidant and pro-inflammatory
pathways, since the dysfunction was partially prevented
by pre-incubation with the NADPH oxidase blocker apo-
cynin (Figure 7A), the superoxide anion scavenger tempol
(Figure 7B), the COX blocker indomethacin (Figure 7C),
or the iNOS inhibitor 1400 W (Figure 7D). In microvessels
from diabetic rats treated with anakinra (160 mg/Kg/day
for 3 days), and further incubated in the presence of apocy-
nin, tempol, indomethacin, or 1400 W, the ACh-induced
relaxations were similar to those obtained in vessels from
control animals, without any remaining endothelial dys-
function (Figures 7A, 7B, 7C, and 7D). None of the drugs
used modified endothelium-dependent relaxations in ves-
sels from non-diabetic animals (Figures 3B, 3C, 3D, and
3E), or the contractile responses evoked by 1 μmol/L NA
in control or diabetic animals (data not shown).Plasma IL-1β and TNF-α determinations
The pro-inflammatory cytokines IL-1β and TNF-α were
determined by ELISA in plasmatic samples from control
diabetic rats, either without treatment or after receiving
anakinra (100 mg/Kg/day for 3 days; 100 mg/Kg/days
for 7 days, or 160 mg/Kg/day for 3 days). As compared
with control animals, no significant changes in cytokine
levels were observed in untreated diabetic animals nei-
ther in control animals treated with anakinra (Table 1).
However, anakinra treatment (100 mg/Kg/day for 7 days
and 160 mg/Kg/day for 3 days) reduced significantly the
plasmatic levels of IL-1β and TNF-α in diabetic animals
(Table 1).
Discussion
It is well known that the development of an inflammatory
environment in the vasculature is followed by a clear im-
pairment of endothelial function; indeed, acute systemic
inflammation with Salmonella typhi vaccine produces a
temporary but profound dysfunction of human arterial
Figure 4 IL-1β increases vascular NADPH oxidase activity.
(A) NADPH oxidase activity in microvascular mesenteric preparations
from control SD rats after 30 min stimulation with IL-1β (1, 2.5, and
10 μg/mL). Bars represents the mean ± SE of the relative light units
(RLU) obtained in 3 different experiments using tissues from 6 animals.
(B) NADPH oxidase activity in microvascular mesenteric preparations
from control SD rats after 30 min stimulation with 2.5 μg/mL IL-1β,
either alone and in the presence of 100 μg/mL anakinra or 10 μmol/L
apocynin. Bars represent the mean ± SE of the relative light units (RLU)
obtained in 3 experiments using tissues from 9 animals. *p < 0.05 vs
basal; †p < 0.05 vs IL-1β.
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which is related to cytokine production [29,30]. On the
other hand, pro-inflammatory cytokines, such as TNF-α,
induce endothelial dysfunction in animal models and
humans [31-33]. Moreover, there is increasing evidence of
a role for pro-inflammatory cytokines in the development
of vascular diseases, particularly diabetic vasculopathy
[11-15]. In this line, it has been proposed that TNF-α can
be one of the mediators for the insulin resistance and
endothelial dysfunction associated to type 2 diabetes
mellitus [33-35].
Endothelial dysfunction produced by IL-1β has been
previously reported in isolated rat mesenteric microvesselsusing both short (30 min) [22] and longer (14 h) [24]
incubation times with the cytokine. We selected a 2 h
period of IL-1β treatment as it produced a selective
concentration-dependent endothelial dysfunction, without
affecting the contractile or relaxant responses of the
vascular smooth muscle layer. Moreover, the pro-
inflammatory responses triggered by IL-1β were not
entirely developed after this short incubation time with the
cytokine, as indicated by the lack of activity of pro-
inflammatory enzymes such as COX and iNOS. Therefore,
in the present conditions, we assume that the impairment
of the endothelium-dependent relaxations evoked by IL-1β
in isolated segments from non-diabetic animals was mainly
mediated by an enhancement of superoxide anion produc-
tion produced by the activation of NADPH oxidase. Endo-
thelial alteration by IL-1β was requiring the activation of
IL-1 receptors, since the pre-incubation of the vascular
segments with the recombinant human antagonist of IL-1
receptors anakinra led to a concentration-dependent re-
covery of the endothelial dysfunction evoked by IL-1β. In
addition, anakinra also blocked NADPH oxidase activation
by IL-1β to the same extent than apocynin, further sup-
porting the role for NADPH oxidase-derived superoxide
anions as mediators of the cytokine-induced endothelial
dysfunction.
Increased production of IL-1β has been linked to a
pro-inflammatory environment in the pancreatic islets
that leads to beta-cell dysfunction and death in type 2
diabetes mellitus [36,37]. It has been also reported that
IL-1β may have a role in the pathogenesis of diabetic
retinopathy [17]. Furthermore, an enhanced expression
of IL-1β in high glucose conditions has been described
in human monocytes and macrophages [38-40], human
pancreatic islets [36], and human aortic endothelium
[41], while the up-regulation of IL-1β has been described
in the retina and retinal vessels from diabetic rats [19].
Moreover, lower adipose tissue inflammation occurs in
knock-out mice for interleukin-1 receptor-I receiving a
high fat-diet, although these animals present similar im-
mune cell recruitment than controls [42].
Based on these studies, the human recombinant anta-
gonist of IL-1 receptors anakinra was tested in patients
with type 2 diabetes mellitus, showing an improvement of
glycaemia and beta cell secretory function, as well as a
reduction of systemic markers of inflammation [19], which
were maintained for several months after treatment with-
drawal [43]. Furthermore, studies in experimental models
indicate that IL-1 receptor antagonists reduce hypergly-
caemia and inflammation in type 2 Goto-Kakizaki diabetic
rats [44,45], and mice with diet-induced hyperglycaemia
or obesity [46,47]. Moreover, anakinra improves cho-
lesterol and adiponectin levels levels in db-/db- diabetic
mice, reducing the ischemia-induced endoplasmic reti-
culum stress and inflammation [48].
Figure 5 Anakinra improves endothelial function in diabetic rats. Effects of treatment with anakinra (AK) (A; 100 mg/Kg/day for 3 days),
(B; 100 mg/Kg/day for 7 days), and (C; 160 mg/Kg/day for 3 days) on the endothelium-dependent relaxations to ACh (0.1 nmol/L to 10 μmol/L)
in isolated mesenteric arteries from control and two weeks evolution streptozotocin-induced diabetic SD rats. Data are expressed (means ± SE) as
the percentage of the previous contraction induced with 1 μmol/L NA. The number of segments used for every curve, which were obtained from
4 to 10 animals, as well as the statistical significance are in parenthesis.
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ceptor signalling on the development of atherosclerosis
has been clearly demonstrated in knock-out mice models
for these receptors [49-51]. Interestingly, treatment with
anakinra ameliorates the cardiac remodelling process in
experimental acute myocardial infarction in rats [52],
while in humans anakinra reduces the inflammatory
responses observed in patients with heart failure after
myocardial infarction [53,54]. Moreover, anakinra induces
a recovery of the endothelial dysfunction in patients
with rheumatoid arthritis [55]. Therefore, at present,
interleukin-1 receptor inhibition is offering an interesting
anti-inflammatory approach for treating not only diabetic
patients, but also cardiovascular diseases, such as athero-
sclerosis [56].The experiments with exogenous IL-1β were consist-
ent with our hypothesis about the possible role for this
cytokine as mediator of diabetic endothelial dysfunction.
Therefore, we next aimed to determine whether this
early endothelial alteration during diabetes, which occurs
both in experimental models and patients and is closely
related with enhanced oxidative stress [1-9], might be
linked to mechanisms triggered by IL-1β and recovered
by a competitive antagonist of IL-1 receptors, such as
anakinra. As a recent-onset model of diabetes mellitus pre-
senting endothelial dysfunction, we used streptozotocin-
induced diabetic rats with two weeks of evolution, which is
the earliest time required to observe endothelial dysfunc-
tion in this experimental model [7]. This point was first
checked in the present study, since other diabetic models,
Figure 6 Anakinra reduces vascular NADPH oxidase activity
and inflammation in diabetic rats. (A) NADPH oxidase activity in
microvascular mesenteric preparations from control and two weeks
evolution streptozotocin-induced diabetic SD rats, either untreated or
treated for 3 days with anakinra (AK; 160 mg/Kg/day). Some samples
also received, before determination, 10 μmol/L apocynin. Bars represent
the mean ± SE of the relative light units (RLU) obtained in at least 3
experiments using tissues from 12 different animals. (B) Representative
photomicrographs (20X) of microscopic sections of control and diabetic
rat aorta, either untreated or receiving AK (160 mg/Kg/day, 3 days)
hybridized with an oligonucleotide with the NF-κB consensus site.
Preparations without probe were used as negative controls and a
200-fold excess of unlabeled probe was used to test the specificity of
the technique. Arrows indicate stained nuclei. (C) Quantitative analysis
of the number of NF-κB stained nuclei by squared micrometers in the
aorta from control and diabetic rats, either untreated or receiving AK.
Bars (mean ± SE) represent the fold increase over untreated control
stained nuclei, which averaged 0.73 ± 0.09/10,000 μm2. At least 3
different animals were employed in every case. *p < 0.05 vs non-diabetic
control rats; †p < 0.05 vs diabetic rats; #p < 0.05 vs AK-treated
diabetic rats.
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preserved endothelium-dependent relaxations in these
early phases of the disease [57]. Also, as previouslyreported in our laboratory [5-8], we observed a recovery
of the diabetes-induced endothelial dysfunction by scaven-
ging superoxide anions, which indicates a crucial role for
oxidative stress. Moreover, in agreement with data pre-
viously reported by others [58,59], our results clearly sug-
gested that both the enhancement of oxidative stress and
the endothelial dysfunction in this diabetic model were re-
lated to increased NADPH oxidase activity, since both
alterations were similarly antagonised by the NADPH oxi-
dase inhibitor apocynin. Our results also indicate an im-
portant activation of the inflammatory pathways into the
vascular wall, linked to diabetes mellitus, based on the
marked increase for NF-κB activation, together with the
relevant participation for pro-inflammatory enzymes, like
COX and iNOS, in the mechanisms producing endothelial
dysfunction.
Being an early indicator for cardiovascular disease, pre-
vention of the diabetic endothelial dysfunction is arising as
an important therapeutic target that may not be reached
with current antidiabetic treatments [60]. Interestingly, the
acute treatment for 3 days of the streptozotocin-induced
diabetic rats with 100 or 160 mg/Kg/day anakinra, which
are at the higher dose range reported in experimental
models [52,61], resulted in significant improvements of
endothelium-dependent relaxations that seemed to be
closely associated to the normalization of the NADPH oxi-
dase activity in the vascular wall, as well as to a significant
reduction in the vascular inflammatory responses. To our
knowledge, this is the first report demonstrating that ana-
kinra improves diabetic endothelial dysfunction. Further-
more, our results strongly suggest that the mechanism for
such effect involves the antagonism of IL-1 receptors,
which interferes with the IL-1β-evoked NADPH oxidase
activity, leading to a lower NF-κB activation and reducing
the enhanced activity of COX and iNOS. It is worth to
note that the dose of 160 mg/Kg/day of anakinra produces
effects only slightly higher than 100 mg/Kg/day, while
the improvement of the endothelial dysfunction by
100 mg/Kg/day anakinra did not increase after prolonging
the treatment up to 7 days. This is likely because we were
using maximal or submaximal concentrations of the IL-1
receptor antagonist. Therefore, any possible extrapolation
to patients should consider the effects of longer adminis-
tration of much lower doses of anakinra.
We next aimed to study a possible role for enhanced
circulating IL-1β in the observed diabetic endothelial
dysfunction, determining its plasmatic levels in the
streptozotocin-induced diabetic rats, as well as those of
other pro-inflammatory cytokines, like TNF-α. However,
despite the results obtained with anakinra, we could not
detect any increase in the circulating concentrations of
both cytokines after two weeks evolution of diabetes.
This is in agreement with previous results determining
IL-1β in this model [62], although increased serum levels
Figure 7 Anakinra attenuates the vascular pro-oxidant and pro-inflammatory environment leading to diabetic endothelial dysfunction.
Effect of (A) tempol (100 μmol/L), (B) apocynin (Apo, 10 μmol/L), (C) indomethacin (Indo; 10 μmol/L), or (D) 1400 W (10 μmol/L) on the impairment of
the endothelium-dependent relaxations evoked by ACh (0.1 nmol/L to 10 μmol/L) observed in diabetic SD rats, either untreated or receiving anakinra
(AK, 160 mg/Kg/dasy during 3 days). Data are expressed as the percentage of the pre-contraction induced with 1 μmol/L NA. The number of segments
used for every curve, which were obtained from 3 to 5 animals, as well as the statistical significance are in parenthesis.
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cin-induced type 2 diabetic rats [63]. Indeed, an enhance-
ment in the plasmatic IL-1β or TNF-α concentrations is
even hardly detected in diabetic patients [64-66]. There-
fore, it seems reasonable to suggest that an early tissular
inflammatory response into the vascular wall can be re-
sponsible, at least in part, for the diabetic endothelial dys-
function. Consistently, enhanced tissular inflammatory
mediators have been described in vitreous samples fromTable 1 Plasmatic levels of IL-1β and TNF-α (pg/mL) in contro
diabetic SD rats, both untreated or receiving i.p. anakinra (AK
Untreated AK (100 mg/Kg/day for 3 days)
Control IL-1β 82.61 ± 5.02 78.59 ± 18.02
TNF-α 11.52 ± 2.71 12.82 ± 3.08
Diabetic IL-1β 83.88 ± 10.84 57.11 ± 5.75
TNF-α 11.22 ± 2.05 8.26 ± 2.13
Data are expressed as mean ± SE of 4 to 10 determinations. *p < 0.05 vs respectivepatients with proliferative diabetic retinopathy [67], as well
as in kidney and liver from streptozotocin-induce diabetic
rats [68,69].
Conclusions
The present results indicates that the development of
endothelial dysfunction in a short-term model of experi-
mental type 1 diabetes can be related to an IL-1 receptor-
mediated activation of vascular NADPH oxidase, leadingl and two weeks evolution streptozotocin-induced
)
AK (100 mg/Kg/day for 7 days) AK (160 mg/Kg/day for 3 days)
77.85 ± 18.55 90.44 ± 18.47
12.39 ± 1.30 10.21 ± 4.34
45.17 ± 8.48* 42.89 ± 4.92*†
3.48 ± 0.82*† 3.43 ± 1.27*†
untreated rats; †p < 0.05 vs respective control group.
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inflammatory pathways into the vascular wall. Whether
this mechanism can be extrapolated to a chronic situation
or whether it may be applied to diabetic patients remains
to be established. However, it may provide new insights to
further investigate the therapeutic use of IL-1-receptor
antagonists to obtain vascular benefits in patients with
diabetes mellitus and/or atherosclerosis.
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